Accelerated Pathways and Commercial Consequences
October 29, 2015 - October 30, 2015
Join PAREXEL and The Network for Excellence in Health Innovation (NEHI) for a forum on commercial outcomes of expedited regulatory approval.
Learn the risks and benefits of accelerating the development and approval process, as well as payer reaction, reimbursement rates and market access. Plus, hear first-hand insights from our proprietary research, The Commercial Impact of Acceleration and add your perspective on these important topics during facilitated sessions.
Featured topics and speakers include:
To Accelerate or Not: Peer Perspectives on Decision Criteria
Craig Lipset, Head of Clinical Innovation, Pfizer
Oved Amitay, Head of Commercial, Alnylam Pharmaceuticals
Meeting the Data Challenge: Maintaining Value and Managing Risk
Mohan Bala, Vice President, HEOR, Sanofi
Panel Discussion: Defining Value: Payer Perspectives
Caleb DesRosiers, EVP & General Counsel, CareMed Pharmaceutical Services, Inc.
Michael Sherman, Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care
William B. Dreitlein, Pharm.D., BCPS, Institute for Clinical and Economic Review (ICER) formerly Portfolio Lead, Market Access Solutions, Envision Pharma Group
Rules of Engagement in a New Healthcare Ecosystem
David Meeker, MD, President and CEO, Genzyme
Ritesh Patel, Chief Digital Officer, Ogilvy CommonHealth Worldwide
Who Should Attend
This event is complimentary for biopharmaceutical and payer executives.
The Colonnade Hotel
120 Huntington Avenue
Boston, Massachusetts 02116